Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Janus Henderson Group increased its Xeris Biopharma stake by 322.8% in the first quarter, bringing its holdings to 295,489 shares worth approximately $1.71 million. Institutional investors collectively own 42.75% of XERS.
• Xeris reported quarterly revenue of $92.1 million, exceeding estimates, but its adjusted loss of $0.18 per share missed expectations by $0.19. Insiders have sold 266,499 shares worth nearly $2.0 million over the past three months.
• Analyst sentiment remains moderately positive, with four Buy ratings and three Holds and a consensus price target of $10.80, compared with the stock’s reported price of $7.93.

Janus Henderson Group PLC lifted its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 322.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 295,489 shares of the company's stock after acquiring an additional 225,602 shares during the period. Janus Henderson Group PLC owned 0.17% of Xeris Biopharma worth $1,713,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Cetera Investment Advisers raised its stake in Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company's stock valued at $216,000 after purchasing an additional 1,735 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company's stock worth $63,000 after purchasing an additional 1,820 shares during the last quarter. Royal Bank of Canada boosted its stake in Xeris Biopharma by 6.5% during the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company's stock worth $304,000 after purchasing an additional 2,351 shares during the last quarter. AlphaCentric Advisors LLC grew its holdings in shares of Xeris Biopharma by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company's stock worth $266,000 after buying an additional 2,494 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth $25,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 16,666 shares of Xeris Biopharma stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $8.01, for a total value of $133,494.66. Following the sale, the insider owned 1,144,462 shares in the company, valued at $9,167,140.62. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 15,000 shares of the company's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $8.02, for a total value of $120,300.00. Following the completion of the transaction, the insider directly owned 1,676,126 shares in the company, valued at approximately $13,442,530.52. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 266,499 shares of company stock valued at $1,996,417. 4.35% of the stock is currently owned by company insiders.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $7.93 on Monday. The firm has a 50 day simple moving average of $7.68 and a 200-day simple moving average of $6.79. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -72.09 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $10.08.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.03 EPS for the current year.

Analysts Set New Price Targets

XERS has been the topic of several research reports. Wall Street Zen downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Weiss Ratings raised shares of Xeris Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, Xeris Biopharma currently has an average rating of "Moderate Buy" and a consensus price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source